Novo says AI is accelerating drug discovery as it expands partnerships with Anthropic, OpenAI and Valo

Novo says it is using AI across drug discovery and development, reporting more than 30 strategic AI partnerships and more than 600 AI and digital professionals working with scientists as it tries to expand beyond Ozempic and Wegovy. The company says 2026 AI work has produced a more than 3-fold improvement in target hit rate, a 90% reduction in time spent on trial-site selection and population analysis, and 10-fold faster clinical study report generation.